Speaker(s): 

Muhammad Usman Haider, MD, Staff Member, Geisinger - has nothing to disclose.

Moderator(s): 

Anil Singh, MD, Staff Member, Geisinger - has nothing to disclose

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• Review the historical evolution of heart failure and discuss the current epidemiology, disease burden, and readmission rates.
• Define heart failure and describe its underlying pathophysiology, including the neurohormonal mechanisms that drive disease progression.
• Recognize the clinical presentation of heart failure and apply an evidence-based diagnostic approach, including the role of biomarkers and cardiac imaging.
• Differentiate the major classifications of heart failure based on ejection fraction, symptom severity, and staging, and understand their clinical implications.
• Summarize contemporary guideline-directed medical therapy (GDMT) and management strategies across the spectrum of heart failure.
• Discuss the indications for device-based therapies and review emerging advancements that are shaping the future of heart failure management.

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Anil Kumar Singh, MD, Roop Parlapalli, MD, FHM, FACP, Lakshmi Rani Gollamudi, MD, Christopher DeFrancesco PharmD, RPH, Mary Ellen Berry, PA-C, Alexa Kerecman, CRNP, Michael Madden, DO, and Keshav Bhandari, MD have no identified disclosures. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None